To support the movement of less exposure surgery (LES) of the spine in ambulatory surgery centers (ASCs), KICVentures announced the formation of NANISX. The company comprises the holdings of KICVentures’ portfolio companies: NanoFUSE Biologics, InSpan and Sacrix.
NANISX will be divided into two ASC divisions: NANISX Pain, focused on interventional pain management, and NANISX Ortho-Neuro.
NANISX will have three outpatient spine technologies as a platform to offer the ASC:
Sacrix offers multi-threaded screws and fluted anti-rotational implants, including a novel lateral-oblique percutaneous technique that can be done quickly with almost no bleeding through a 1.5 cm incision.
InSpan’s midline mini-open percutaneous interlaminar-interspinous device (IPD) is seeing growing adoption for treating spinal stenosis and for spinal fusion without the need for pedicle screws or interbody cages.
NanoFUSE Biologics is reportedly the world’s only FDA-cleared fiber-based synthetic bioactive glass combined with demineralized bone matrix for regenerative bone formation.
NANISX portfolio of technologies are revenue and EBITDA positive and should grow rapidly with the expected addition of a new Chief Executive Officer (CEO) to be announced soon. The company has also initiated the listing process to prepare for an initial public offering.
To support the movement of less exposure surgery (LES) of the spine in ambulatory surgery centers (ASCs), KICVentures announced the formation of NANISX. The company comprises the holdings of KICVentures' portfolio companies: NanoFUSE Biologics, InSpan and Sacrix.
NANISX will be divided into two ASC divisions: NANISX Pain, focused on...
To support the movement of less exposure surgery (LES) of the spine in ambulatory surgery centers (ASCs), KICVentures announced the formation of NANISX. The company comprises the holdings of KICVentures’ portfolio companies: NanoFUSE Biologics, InSpan and Sacrix.
NANISX will be divided into two ASC divisions: NANISX Pain, focused on interventional pain management, and NANISX Ortho-Neuro.
NANISX will have three outpatient spine technologies as a platform to offer the ASC:
Sacrix offers multi-threaded screws and fluted anti-rotational implants, including a novel lateral-oblique percutaneous technique that can be done quickly with almost no bleeding through a 1.5 cm incision.
InSpan’s midline mini-open percutaneous interlaminar-interspinous device (IPD) is seeing growing adoption for treating spinal stenosis and for spinal fusion without the need for pedicle screws or interbody cages.
NanoFUSE Biologics is reportedly the world’s only FDA-cleared fiber-based synthetic bioactive glass combined with demineralized bone matrix for regenerative bone formation.
NANISX portfolio of technologies are revenue and EBITDA positive and should grow rapidly with the expected addition of a new Chief Executive Officer (CEO) to be announced soon. The company has also initiated the listing process to prepare for an initial public offering.
Copy to clipboard 
